WASHINGTON--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company, announced it has successfully met its endpoints for its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), which studied SuperOxygenation Therapy for Acute Myocardial Infarction (AMI) patients. The results were presented today during a late-breaking session at the 19th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in Washington D.C. The data will be submitted shortly to the FDA as part of the company’s Premarket Approval (PMA) application.
